Most Read News

The brokerage said that its client base rose 5.2% to 9.21 million in March 2022 as against 8.76 million in February 2022.

On 08 April 2022

The offer received bids for 6.74 crore shares as against 85 lakh shares on offer.

The India Risk Management Awards recognizes individuals and organizations who have significantly added to the understanding and practice of risk management.

Business Wire India Asit Oberoi – Regional Head South Asia, iPid The ground-breaking fintech of International Payments- iPiD, today announced its launch in the Indian market. iPiD is a technological innovative initiative for financial transactions cutting across the political borders of nations and financial borders of currencies. And all this through phone numbers linked to the bank accounts of the recipient. This eliminates the margin […]

Maruti Suzuki India announced that over the past year, the cost of Companys vehicles continue to be adversely impacted due to increase in various input costs. Therefore, it has become imperative for the Company to pass on some impact of the above additional costs to customers through a price hike. The Company has planned this price rise in April, 2022. The increase shall vary for […]

Business Wire India Experian, a global information services company which provides technology, data and analytics to its clients, was named the top established leader in digital identity in Juniper Research’s Digital Identity Competitor Leaderboard.The report provides a five-year forecast for the digital identity sector and cites Experian and its CrossCore™ platform as the market leader in capacity, capability, and product strength.   This press release […]

JSW Energy Ltd saw volume of 2.72 lakh shares by 10:51 IST on BSE, a 7.83 fold spurt over two-week average daily volume of 34761 shares

The Buildings & Factories business of the EPC major, Larsen & Toubro (L&T) secured significant contracts from multiple clients.

The Pharma major received DCGI approval for Thymosin Alpha-1 (Immunocin α - A Brand of Gufic for the said drug) as an add-on therapy for the treatment of moderate-to-severe COVID-19 patients.